332079-42-2

Basic information

• Product Name: (E)-3-(3,4-dihydroxyphenyl)-N-phenylacrylamide
• Synonyms: (E)-3-(3,4-dihydroxyphenyl)-N-phenylacrylamide
• CAS NO: 332079-42-2
• Molecular Weight: 255.273
• Mol File: 332079-42-2.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: (E)-3-(3,4-dihydroxyphenyl)-N-phenylacrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(3,4-dihydroxyphenyl)-N-phenylacrylamide(332079-42-2)
• EPA Substance Registry System: (E)-3-(3,4-dihydroxyphenyl)-N-phenylacrylamide(332079-42-2)

Safety Data

• Hazardous Substances Data: 332079-42-2(Hazardous Substances Data)

Upstream product

• 331-39-5 caffeic acid 
• 62-53-3 aniline 
• 121-33-5 vanillin 
• 54429-62-8 (E)-3-(3,4-bis(benzyloxy)phenyl)acrylic acid 
• 5447-02-9 3,4-dibenzyloxybenzaldehyde 
• 203571-40-8 3-(3,4-bis-benzyloxy-phenyl)-acrylic acid ethyl ester 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 331-39-5 caffeic acid 
• 861897-00-9 3,4-bis[(methoxycarbonyl)oxy]cinnamic acid 
• 5396-64-5 methyl (E)-3-(3,4-dimethoxyphenyl)acrylate 
• 14737-89-4 3,4-dimethoxy-trans-cinnamic acid 
• 123019-93-2 (E)-[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]aminobenzene 
• 15580-32-2 malonanilic acid 

Relevant articles and documents

Evaluation of caffeic acid amide analogues as anti-platelet aggregation and anti-oxidative agents

A series of amides of caffeic acid were synthesized and evaluated for their anti-platelet and anti-oxidative activities. N-(2-Bromo-phenyl)-3-(3,4- dihydroxy-phenyl)-acrylamide (12) and N-(3-Bromo-phenyl)-3-(3,4-dihydroxy- phenyl)-acrylamide (13) exhibite

Skin Whitening Composition Comprising Caffeic Acid Derivatives as the Active Ingredients

The present invention relates to a skin whitening composition containing a new caffeic acid derivative compound as an active ingredient. According to the present invention, the caffeic acid derivative compound can be developed for a skin whitening cosmetic product or for a medicine for the hyperpigmentation of melanin because having skin whitening activity by inhibiting the biosynthesis of melanin in melanocytes.

Synthesis and biological evaluation of caffeic acid derivatives as potent inhibitors of α-MSH-stimulated melanogenesis

We have disclosed our effort to develop caffeic acid derivatives as potent and non-toxic inhibitors of α-MSH-stimulated melanogenesis to treat pigmentation disorders and skin medication including a cosmetic skin-whitening agent. The SAR studies revealed t